Evidence map›Paper›PMID 33483308›Full record

ArticleApplied and environmental microbiology2021

Amoxicillin-Clavulanic Acid Resistance in the Genus

Leonardo Mancabelli, Walter Mancino, Gabriele Andrea Lugli, Chiara Argentini, Giulia Longhi, Christian Milani, Alice Viappiani, Rosaria Anzalone, Sergio Bernasconi, Douwe van Sinderen and 2 more

3 registry-linked trialsOpen access · greenAbstract read
In one paragraph

Article in Applied and environmental microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05840588 nacompletednot on this mapstarted 2023, after this paper: background citation

Effect of Bifidobacterium Breve PRL2020 (an Amoxicillin-Clavulanate-Resistant Strain) on Gastrointestinal Symptoms and Gut Microbiota Composition in Children Treated With Amoxicillin or Amoxicillin/Clavulanate: Results of a Pediatric, Multicenter, Randomized, Controlled, Prospective Study

TypeinterventionalSponsorLiaquat University of Medical & Health SciencesRan2023 to 2025Enrolled121ConditionsBacterial InfectionsArmsAntibiotic Treatment, Probiotic Bifidobacterium breve PRL2020 (Brevicillin®) treatment
NCT06850714 nanot yet recruitingnot on this mapstarted 2025, after this paper: background citation

Evaluation of the Use of Bifidobacterium Breve PRL2020 in Preventing Side Effects From Amoxicillin or Amoxicillin/Clavulanic Acid Antibiotic Use: A Randomized Controlled Trial

TypeinterventionalSponsorLiaquat University of Medical & Health SciencesRan2025 to 2025Enrolled800ConditionsAntibiotic Side EffectArmsBifidobacterium breve PRL2020 (Brevicillin®), Amoxicillin or Amoxicillin/Clavulanic Acid
NCT07234448 nacompletednot on this mapstarted 2025, after this paper: background citation

Evaluation of the Use of a Probiotic Containing Bifidobacterium Breve PRL2020 in Oral Drops in Preventing Side Effects From Amoxicillin or Amoxicillin/Clavulanic Acid Antibiotic Use: a Multicentre, Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial

TypeinterventionalSponsorLiaquat University of Medical & Health SciencesRan2025 to 2026Enrolled1,100ConditionsAntibiotic-associated DiarrheaArmsBrevicillin® gocce (Bifidobacterium breve PRL2020), Placebo (matching oil drops)
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 31 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Role ofFrontiers in pediatrics · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Ecology- and genome-based identification of theApplied and environmental microbiology · 2024
    Article
  10. Genomic and ecological approaches to identify theFrontiers in microbiology · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Microorganisms · 2023
    Article
  16. Identification of a prototype human gutFrontiers in microbiology · 2023
    Article
  17. Article
  18. Article
  19. Article
  20. Prospects for Antibacterial Discovery and Development.Journal of the American Chemical Society · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Leonardo Mancabelli *Laboratory of Probiogenomics, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy.
Walter Mancino *Laboratory of Probiogenomics, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy.
Gabriele Andrea LugliLaboratory of Probiogenomics, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy.
Chiara ArgentiniLaboratory of Probiogenomics, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy.
Giulia LonghiLaboratory of Probiogenomics, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy.
Christian MilaniLaboratory of Probiogenomics, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy.
Alice ViappianiGenProbio srl, Parma, Italy.
Rosaria AnzaloneGenProbio srl, Parma, Italy.
Sergio BernasconiMicrobiome Research Hub, University of Parma, Parma, Italy.
Douwe van SinderenSchool of Microbiology & APC Microbiome Institute, University College Cork, Cork, Ireland.ORCID 0000-0003-1823-7957
Marco VenturaLaboratory of Probiogenomics, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy.ORCID 0000-0002-4875-4560
Francesca TurroniLaboratory of Probiogenomics, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy francesca.turroni@unipr.it.ORCID 0000-0001-5363-0231
University of Parma · ITUniversity College Cork · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amoxicillin-clavulanic acid (AMC) is one of the most frequently prescribed antibiotic formulations in the Western world. Extensive oral use of this antimicrobial combination influences the gut microbiota. One of the most abundant early colonizers of the human gut microbiota is represented by different taxa of the

Indexed as

Amoxicillin-Potassium Clavulanate CombinationAnti-Bacterial AgentsBifidobacteriumChildChild, PreschoolDrug Resistance, BacterialGastrointestinal MicrobiomeHumansInfantAmoxicillin-Potassium Clavulanate CombinationAnti-Bacterial Agentsantibioticsbifidobacteriacomparative genomics

Identifiers

PMID33483308
PMCPMC8091617
OpenAlexW3121388576

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.